How to Reconstitute Sermorelin

Sermorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), also referred to as GRF 1-29 or GHRH(1-29)NH2. It is a 29-amino-acid amidated fragment corresponding to the N-terminal portion of endogenous GHRH, and it is classified as a GHRH analogue within the broader group of performance-enhancing peptides marketed as research compounds [2]. The evidence block supplied for this page does not provide a sequence string, molecular formula, or molecular weight for sermorelin, so none are stated here. In the published literature, sermorelin is grouped alongside tesamorelin, CJC-1295 with and without Drug Affinity Complex, the growth hormone secretagogues GHRP-2, GHRP-6, hexarelin and ipamorelin, the GH fragment AOD9604 (hGH 176-191), and IGF-1 analogues as agents intended to modulate the GH-IGF-1 axis [2].

The work described in the evidence centres on the GHRH receptor pathway and its downstream modulation of growth hormone secretion and the GH-IGF-1 axis [2].

Research Studies

Sermorelin and the GH-IGF-1 axis in self-administration contexts

A review of performance-enhancing peptides described sermorelin as one of the GHRH analogues most commonly encountered in clinical practice and in online self-administration protocols, alongside tesamorelin and the CJC-1295 variants [2]. The same review framed these agents as unregulated peptides marketed as research compounds and intended to modulate the GH-IGF-1 axis [2]. This is a descriptive and regulatory observation about how the compounds appear in practice, not a report of a controlled trial of sermorelin itself.

Sermorelin and analytical detection in urine

GHRH and its synthetic analogues, including sermorelin, are considered performance-enhancing substances and are prohibited by the World Anti-Doping Agency [12]. Analysis of GHRH and its analogues in urine presents significant analytical challenges because of their inherent in vivo instability and rapid clearance, and nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry has been examined as an approach to that problem [12]. This work is analytical and detection-focused; it does not report physiological outcomes.

Sermorelin and the peptide therapeutics literature in sport

Critical reviews of peptide and peptide-analogue use in recreational and professional sport and bodybuilding have situated GHRH analogues within a shift away from anabolic-androgenic steroids toward agents marketed as more selective and ostensibly safer alternatives [10]. Reviews of peptide therapies for musculoskeletal injuries and athletic performance have similarly noted that peptide use in sports medicine is expanding, driven by demand for accelerated injury recovery and performance enhancement, while emphasising that many peptide drugs have undergone rigorous appraisal and many have not [9]. Sermorelin appears in this literature as part of the class under discussion rather than as the subject of a dedicated efficacy trial.

Sermorelin and orthopaedic signalling pathways

A review of therapeutic peptides in orthopaedics described peptides as adjuncts that act on signalling networks including PI3K/Akt, mTOR, MAPK, TGF-beta and AMPK, influencing tissue regeneration [11]. This is a class-level statement about peptide therapeutics generally and is not specific to sermorelin; it is included here because it defines the mechanistic vocabulary in which GHRH analogues are sometimes discussed.

GHRH analogue tesamorelin and liver fat in adults with fatty liver disease

A randomised, double-blind, placebo-controlled Phase II study evaluated whether daily subcutaneous tesamorelin, a GHRH analogue, reduces liver fat in adults with fatty liver disease [3]. Participants received tesamorelin or matching placebo for 52 weeks, with standardised lifestyle counselling in both groups, and liver fat was quantified by MRI-proton density fat fraction; safety monitoring included glucose metrics and IGF-1 [3]. This study concerns tesamorelin, not sermorelin, and is reported here as evidence about the GHRH analogue class.

GHRH analogue tesamorelin and physical function in adults with HIV

A clinical trial examined whether tesamorelin improves physical function and muscle health in adults with HIV when combined with exercise [4]. The rationale given was that people with HIV experience earlier impairments in physical function and earlier, more rapid development of frailty than the general population, and that exercise is less effective and harder to sustain in that group [4]. Again, the agent studied was tesamorelin.

GHRH analogue tesamorelin and body composition in HIV lipodystrophy

A single-arm prospective study examined the effect of tesamorelin on body composition in patients with HIV lipodystrophy and central adiposity [7]. Participants underwent body composition testing, adipose tissue biopsy, metabolic rate measurements and insulin sensitivity assessment before, and at 6 and 12 months after, daily subcutaneous injections of tesamorelin 2 mg [7].

GHRH analogue tesamorelin and nonalcoholic fatty liver disease with cardiovascular risk

A study investigated whether tesamorelin reduces liver fat and inflammation in individuals with obesity and nonalcoholic fatty liver disease, on the basis that individuals with obesity on average secrete less growth hormone and that growth hormone may reduce liver fat and inflammation [6].

GHRH and cognitive function in mild cognitive impairment

A study examined the effects of GHRH on mild cognitive impairment, administering GHRH at 1 mg/day for 10 weeks to subjects with mild cognitive impairment as well as healthy controls [8]. This study used GHRH rather than sermorelin.

GHRH analogue exposure and anterior cervical osteophytes

A case report described a 62-year-old male ex-military recreational bodybuilder, a long-term growth hormone user, who presented with cervicalgia and left shoulder pain [1]. Cervical radiographs and MRI showed multilevel degenerative changes including a prominent anterior osteophyte at C3-C4 with oesophageal compression, and on directed questioning he reported intermittent dysphagia with larger food boluses; he also reported a cervical injury during jiu-jitsu [1]. The report noted that anterior cervical osteophytes can compress the oesophagus and produce dysphagia, that symptomatic osteophytic dysphagia is underdiagnosed despite being common on imaging in older adults, and that the role of systemic anabolic factors in osteophyte growth is poorly characterised [1]. This is a single case report involving growth hormone, not sermorelin, and cannot establish causation.

Comparison of GHRH analogues and related agents in the evidence

What the evidence does not establish

No study in the supplied evidence administered sermorelin to a human population and reported a clinical endpoint. The human trial evidence in this block concerns tesamorelin and GHRH, not sermorelin. The sermorelin-specific material is limited to its appearance in reviews of performance-enhancing peptide use and in analytical chemistry work on urinary detection [2], [12]. Claims about sermorelin's effects in humans, in animals, or in vitro are therefore not supported by this evidence block and are not made here.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report. https://europepmc.org/article/PMC/PMC13375183
• [2] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. https://europepmc.org/article/PMC/PMC13322892
• [3] Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease. https://clinicaltrials.gov/study/NCT07481734
• [4] Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV. https://clinicaltrials.gov/study/NCT06554717
• [5] Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation. https://clinicaltrials.gov/study/NCT06701071
• [6] Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk. https://clinicaltrials.gov/study/NCT03375788
• [7] Body Composition and Adipose Tissue in HIV. https://clinicaltrials.gov/study/NCT03226821
• [8] The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment. https://clinicaltrials.gov/study/NCT02553603
• [9] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. https://pubmed.ncbi.nlm.nih.gov/41966639/
• [10] A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. https://pubmed.ncbi.nlm.nih.gov/41880199/
• [11] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. https://europepmc.org/article/PMC/PMC12753158
• [12] Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. https://pubmed.ncbi.nlm.nih.gov/41138283/